MarketLens
Sign Up
Stock Analysis

ASP Isotopes: Insider Sales Challenge the $300 Million EBITDA Vision

3 months ago
SHARE THIS ON:

ASP Isotopes: Insider Sales Challenge the $300 Million EBITDA Vision

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in
SHARE THIS ON:

Related Articles

What Does a $300,000 Insider Sale Mean for NBIS Investors

What Does a $300,000 Insider Sale Mean for NBIS Investors

6 months ago
Is SSR Mining's $300 Million Buyback a Signal to Buy

Is SSR Mining's $300 Million Buyback a Signal to Buy

8 months ago
Why is JFrog Initiating a $300 Million Share Buyback Now

Why is JFrog Initiating a $300 Million Share Buyback Now

7 months ago
Together AI's $8.3 Billion Valuation: A Neocloud's Challenge to Hyperscaler AI Dominance

Together AI's $8.3 Billion Valuation: A Neocloud's Challenge to Hyperscaler AI Dominance

3 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

Stock News•3 weeks ago

Did ASP Isotopes Inc. Insiders Breach their Fiduciary Duties to Shareholders?

A law firm is soliciting ASP Isotopes shareholders to discuss potential insider fiduciary duty breaches at no cost on a contingent-fee basis. No specific allegations, damages, or timeline are disclose...
ASPI
Stock News•1 months ago

USA Rare Earth: Progress Over Perfection

USA Rare Earth is scaling a vertically integrated rare earths business, targeting $1.85B adjusted EBITDA by 2030 and ~80% FCF conversion, despite skeptical market views on long-term profitability.
USAR
Stock News•2 months ago

ASP Isotopes Issues Letter to Shareholders

ASP Isotopes reported 1H 2026 PET Labs organic revenue growth of over 50% versus 1H 2025, ahead of Q2 results. Three business units are at an inflection point, expected to contribute to near-term prof...
ASPI

Breaking News

View All →
Earnings
Earnings Surprise
Corporate Earnings
EPS Beat/Miss
AI Infrastructure
Analyst Ratings
Biotech & Pharma
Clinical Trials (Phase I, II, III)
M&A
Major Contract Wins

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

2 months ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

2 months ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

2 months ago

Top Headlines

View More →
Stock News•1 hour ago

OpenAI Is Reportedly Raising $30 Billion. Which Chip Stock Gains the Most?

Stock News•1 hour ago

Apple (AAPL) Stock Sinks As Market Gains: What You Should Know

Stock News•1 hour ago

Annaly Capital Management (NLY) Surpasses Q3 Earnings Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Stock Declines While Market Improves: Some Information for Investors

Stock News•1 hour ago

Alphabet Inc. (GOOG) Stock Drops Despite Market Gains: Important Facts to Note